Galenband is a medical technology company developing wearable cardiac monitoring solutions for long-term remote patient monitoring. The company’s wearable telemetry system continuously monitors cardiac function for up to 90 days via a prescription-based platform that supports clinicians with data analysis and reporting capabilities.

Developed by engineers from internationally recognized institutions, Galenband incorporates medical-grade sensors to capture diagnostic-quality cardiac data. The system transmits information without requiring mobile applications, reducing setup requirements compared with traditional monitoring devices such as patch monitors and Holter systems. Galenband integrates wearable hardware with cloud-based analytics to create a connected workflow designed for extended cardiac monitoring.

AI-Supported Reporting

Galenband’s analytics platform automatically receives cardiac data from the wearable device, where advanced algorithms analyze recordings and identify potential abnormalities. The platform generates preliminary reports that are reviewed and validated by Galenband cardiac technicians before reaching the prescribing clinician, helping reduce data analysis time and support clinical review.

The reporting platform is designed to organize long-duration cardiac data into a format that assists clinicians during review. By automating elements of data analysis while maintaining technician validation, Galenband facilitates a workflow that connects continuous monitoring with clinical assessment.

A Growing Epidemic

Atrial fibrillation (AFib) is one of the most common cardiac rhythm disorders, affecting an estimated 49 million people worldwide. As healthcare providers manage a growing number of patients requiring cardiac monitoring, the need for longer-duration solutions that capture intermittent rhythm abnormalities continues to increase.

Detecting irregular heart rhythms often requires monitoring over extended periods, particularly when symptoms may occur unpredictably. Technologies designed for longer observation periods can provide additional opportunities to capture cardiac events that may not appear during shorter monitoring windows.

Bridging the Gap in Cardiac Monitoring

Galenband is developing a prescription cardiac telemetry system designed to bridge the gap between adhesive-based ECG monitors and surgically implanted cardiac monitoring devices. Its single-arm ECG technology records cardiac activity continuously for up to 90 days without recharging or pairing with a smart device.

Through the Galenband cloud portal, clinicians can remotely provision devices, receive automatically transmitted data, and review generated reports. Following a prescription, devices are shipped directly to patients, creating a streamlined workflow for remote monitoring.

While traditional Holter and patch monitors remain widely used, shorter monitoring periods may not capture intermittent cardiac events. Galenband provides a long-duration wearable alternative designed to monitor cardiac activity associated with conditions such as atrial fibrillation without requiring an invasive procedure.

Beyond cardiac monitoring, Galenband’s sensor platform is designed to support future applications across additional healthcare monitoring areas.

Diversity, Equity, and Inclusivity

Galenband values diverse perspectives and experiences as essential elements in developing healthcare technology designed for a broad range of users. The company brings together professionals with expertise across engineering, healthcare, research, and business, creating a multidisciplinary organization focused on cardiac monitoring solutions.

The company’s commercial team includes professionals with experience in healthcare and technology ventures, while its technical team includes individuals from leading research institutions and multinational organizations. Galenband’s development is guided by a commitment to creating accessible cardiac monitoring technology while fostering a workplace where employees can contribute their expertise.

Founded on personal connections to challenges surrounding cardiac health, Galenband brings together individuals united by the goal of developing solutions that support better cardiac monitoring and patient care. The company values collaboration, equal participation, and a workplace culture where different perspectives contribute to innovation.

EDDIE MCDAID | CEO

Eddie McDaid is the Chief Executive Officer of Galenband, a medical technology company developing wearable cardiac monitoring solutions for long-term cardiac telemetry. He is a technology entrepreneur and executive with experience building software businesses, developing technology platforms, and leading early-stage ventures.

Throughout his career, McDaid has focused on technology development, business strategy, and creating solutions that address industry needs. His background includes experience in enterprise software, product development, and executive leadership, with experience building and scaling technology companies.

At Galenband, McDaid leads the company’s efforts to develop wearable cardiac telemetry technology designed to capture continuous diagnostic-quality cardiac data and support long-term monitoring for patients with intermittent arrhythmias.